Clinical trial · Interventional
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00019461CI-TRIAL-00010880completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Primary Peritoneal Cavity Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboxyamidotriazole | Drug | — | UNRESOLVED |
| chemotherapy | Drug | Chemotherapy | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer * Measurable disease by physical exam, radiography, peritoneoscopy, or laparoscopy * No more than 4 weeks since prior peritoneoscopy * No brain metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 4 months Hematopoietic: * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 9.0 g/dL AND/OR * Hematocrit at least 27% Hepatic: * SGOT/SGPT no greater than 3 times upper limit of normal * Bilirubin normal Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 50 mL/min Cardiovascular: * No history of symptomatic cardiac dysrhythmias requiring medication * At least 6 months since prior myocardial infarction * No unstable or newly diagnosed angina Pulmonary: * No obstructive lung disease requiring oxygen therapy Other: * Not pregnant or nursing * HIV negative * Must be able to take oral medication * No concurrent medical condition (e.g., impending bowel obstruction) * No grade 2 or greater residual peripheral neuropathy * No active infection * No other prior or concurrent invasive malignancy within the past 5 years * No history of acute visual loss other than that associated with retinal detachment PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 4 weeks since prior cytokine therapy * No concurrent cytokine therapy to maintain WBC count Chemotherapy: * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carboplatin, or mitomycin) * No other concurrent chemotherapy Endocrine therapy: * At least 4 weeks since prior hormonal therapy * No concurrent corticosteroids at doses greater than physiological replacement doses * No concurrent hormonal therapy Radiotherapy: * At least 4 weeks since prior radiotherapy * No concurrent radiotherapy Surgery: * See Disease Characteristics Other: * No more than 3 prior treatment regimens * At least 1 week since prior systemic antibiotics for infection * No chronic antifungal treatment with antimycotic imidazoles * No concurrent alternative therapies
References
Publications (1)
- RESULTHussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg SM, Raggio M, Oliver VK, Figg WD, Kohn EC. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol. 2003 Dec 1;21(23):4356-63. doi: 10.1200/JCO.2003.04.136. PMID 14645425